Takeda Pharmaceutical is hosting a mini-seminar on the topic *Latest trends in Japan – Medical and Healthcare Market*.
Speaker: Dr. Masato Iwasaki, Takeda Pharmaceutical
Dr. Masato Iwasaki, Director and President of Japan Pharma Business Unit, will be visiting Norway in April. He has kindly offered his time to speak for relevant Norwegian industry players, to share the latest medical and healthcare market trends in Japan. Key words are innovation, cancer, elderly care, dementia, CNS, etc.
Takeda Pharmaceutical Co., Ltd. (“Takeda”) is the largest Japanese pharmaceutical company, with 235 years of history, employing over 31,000 people globally. Revenue for FY2015 was appx. 134 billion NOK. Takeda acquired Nycomed A/S in 2011.
In 2005, Takeda and Pronova BioPharma AS signed a license agreement for the distribution of omega-3 based patented prescription drug “Omacor” for the Japanese market. Since the launch in 2013, sales of the drug (“Lotriga” in Japan) have been very successful with appx. 1,7 billion NOK in FY2015.